(Updated - February 26, 2024 7:57 AM EST)

BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.28), $0.03 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $93.4 million versus the consensus estimate of $89.97 million.

GUIDANCE:

BioCryst Pharma sees FY2024 ORLADEYO revenue of $380-400 million.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.

Earnings Guidance